Influence of <it>SLCO1B1 </it>and <it>CYP2C8 </it>gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers

Influence of <it>SLCO1B1 </it>and <it>CYP2C8 </it>gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers

<p>Abstract</p> <p>Polymorphisms in drug transporter genes and/or drug-metabolising enzyme genes may contribute to inter-individual variability in rosiglitazone pharmacokinetics in humans. We sought to determine the joint effects of polymorphisms in the <it>SLCO1B1 </it>...

Full description

Bibliographic Details
Main Authors:	Aquilante Christina L, Bushman Lane R, Knutsen Shannon D, Burt Lauren E, Rome Lucille Capo, Kosmiski Lisa A
Format:	Article
Language:	English
Published:	BMC 2008-09-01
Series:	Human Genomics
Subjects:	rosiglitazone thiazolidinedione pharmacokinetic pharmacogenetic CYP2C8 SLCO1B1
Online Access:	http://www.humgenomics.com/content/3/1/7

Similar Items

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability
by: Pablo Zubiaur, et al.
Published: (2021-03-01)

Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?
by: Kim CO, et al.
Published: (2017-02-01)

APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY
by: D. A. Sychev, et al.
Published: (2015-09-01)

Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis
by: Thakkar D, et al.
Published: (2017-04-01)

The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia
by: Sychev DA, et al.
Published: (2016-05-01)

A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics
by: Nyarai D. Soko, et al.
Published: (2018-06-01)

Effects of <i>SLCO1B1</i> and <i>SLCO1B3</i> Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
by: Gonjin Song, et al.
Published: (2021-08-01)

SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population
by: Rattanacheeworn P, et al.
Published: (2020-10-01)

<it>SLCO1B1 </it>rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group
by: Krieger José E, et al.
Published: (2011-10-01)

Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation
by: Yun Hyi Ku, et al.
Published: (2017-08-01)

SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals
by: Yalena Prado, et al.
Published: (2015-08-01)

Evaluation of the effect of the carrier of polymorphic variants of the SLCO1B1 gene on efficacy and safety in patients during treatment with statins
by: N. A. Rumyantsev, et al.
Published: (2018-02-01)

Safety and Effectiveness of Rosiglitazone in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease
by: Chao-Hung Wang, et al.
Published: (2006-01-01)

Mechanistic Insights into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol
by: Katarina Kores, et al.
Published: (2021-02-01)

Use of Pharmacogenetic Drugs by the Dutch Population
by: Mohammad A. Alshabeeb, et al.
Published: (2019-07-01)

THE SLCO1B1 GENE POLYMORPHISM AND STATIN-INDUCED MYOPATHY IN RUSSIAN PATIENTS
by: V. I. Petrov, et al.
Published: (2014-10-01)

APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY
by: D. A. Sychev, et al.
Published: (2015-09-01)

The SLCO1B1*15 haplotype associated with lower clinical outcome in Indonesian tuberculosis patients
by: Sunarto Ang, et al.
Published: (2018-03-01)

Rosiglitazone Promotes AQP2 Plasma Membrane Expression In Renal Cells Via a Ca2+-Dependent/cAMP-Independent Mechanism
by: Giuseppe Procino, et al.
Published: (2015-02-01)

SLCO1B1 c.388A > G variant incidence and the severity of hyperbilirubinemia in Indonesian neonates
by: Radhian Amandito, et al.
Published: (2019-06-01)

LncRNA SLCO4A1-AS1 facilitates growth and metastasis of colorectal cancer through β-catenin-dependent Wnt pathway
by: Jiangtao Yu, et al.
Published: (2018-09-01)

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene
by: Trdan Lušin Tina, et al.
Published: (2012-04-01)

Frequencies of two functionally significant SNPs and their haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in six ethnic groups of Pakistani population
by: Tausif Ahmed Rajput, et al.
Published: (2014-06-01)

Increased circulating adiponectin in response to thiazolidinediones: investigating the role of bone marrow adipose tissue
by: Richard J Sulston, et al.
Published: (2016-09-01)

Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects
by: Woo HI, et al.
Published: (2017-04-01)

Side effects of statins in patient with compensated hypothyroidism and SLCO1B1 *5 (c.521T>C) polymorphism
by: Leonid G. Strongin, et al.
Published: (2017-12-01)

Prevalence of dyslipidemia and gene polymorphisms of ABCB1 and SLCO1B1 in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe populations with coronary heart disease in Xinjiang, China
by: Tingting Wang, et al.
Published: (2021-09-01)

Genetic Variations and Frequencies of the Two Functional Single Nucleotide Polymorphisms of SLCO1B1 in the Thai Population
by: Chalitpon Na nakorn, et al.
Published: (2020-06-01)

The impact of acute rosiglitazone on insulin pharmacokinetics at the blood‐brain barrier
by: Demi C. Galindo, et al.
Published: (2020-07-01)

AKR1D1*36 C>T (rs1872930) allelic variant is associated with variability of the CYP2C9 genotype predicted pharmacokinetics of ibuprofen enantiomers – a pilot study in healthy volunteers
by: Kapedanovska Nestorovska Aleksandra, et al.
Published: (2019-09-01)

Increased risk of aspirin-induced gastric mucosal erosion in elderly Chinese men harboring SLCO1B1*1b/*1b while using aspirin and an ACEI or ARB concomitantly
by: Lei Duan, et al.
Published: (2019-11-01)

lncRNA SLCO4A1-AS1 promotes growth and invasion of bladder cancer through sponging miR-335-5p to upregulate OCT4
by: Yang Y, et al.
Published: (2019-02-01)

Association between SLCO1B3 gene polymorphism and prostate cancer risk: A meta-analytic study
by: Qunshan Shen, et al.
Published: (2018-03-01)

The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center
by: Emaad Abdel-Kahaar, et al.
Published: (2019-09-01)

Association Between the Methylation Statuses at CpG Sites in the Promoter Region of the SLCO1B3, RNA Expression and Color Change in Blue Eggshells in Lushi Chickens
by: Zhuanjian Li, et al.
Published: (2019-02-01)

Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children
by: Li Q, et al.
Published: (2019-12-01)

The Effect of Diabetes Mellitus, Insulin, and Thiazolidinediones on Bone Histomorphometry in Streptozotocin-induced Diabetic Postmenopausal Wistar Rats
by: Derya Köseoğlu, et al.
Published: (2021-03-01)

Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis
by: Zhiwei Zhang, et al.
Published: (2017-04-01)

Insertion of LINE-1 Retrotransposon Inducing Exon Inversion Causes a Rotor Syndrome Phenotype
by: Donghu Zhou, et al.
Published: (2020-01-01)

Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy
by: N A Rumyantsev, et al.
Published: (2017-01-01)

Cannot write session to /tmp/vufind_sessions/sess_q50csibdd8huff98jq1e1e3dap